Cardiac Magnetic Resonance for Early Detection of Chemotherapy or Radiation Therapy Induced Cardiotoxicity in Breast Cancer (CareBest)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chemotherapy Induced Cardiotoxicity
- Sponsor
- Yonsei University
- Enrollment
- 2000
- Locations
- 1
- Primary Endpoint
- Decrease in LVEF (left ventricular ejection fraction)
- Status
- Recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
Chemotherapy or radiation therapy-induced cardiotoxicity are well-recognized side effects in patients with cancer. The clinical significance of cardiotoxicity is growing with increasing cancer survivor-ship.
Left ventricular (LV) functional assessment is the standard of reference to diagnose chemotherapy- or radiation therapy-induced cardiotoxicity. The investigators will investigate the usefulness of T1 mapping parameters for early detection and prediction of chemotherapy-, radiation therapy-, or other therapy-induced cardiotoxicity in breast cancer patients This study aimed to achieve early detection of chemotherapy- or radiation therapy-induced cardiotoxicity using T1 mapping magnetic resonance imaging (MRI) and determine a prognostic imaging factor of chemotherapy- or radiation therapy-induced cardiotoxicity in patients treated for breast cancer.
Detailed Description
Screening and follow-up cardiac magnetic resonance imaging (CMR) protocols for diagnosis of cardiotoxicity will be conducted in patients with breast cancer who have received or are planned to receive treatment for breast cancer. The protocol will include T1 and T2 mapping and cine imaging of the LV myocardium.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient with breast cancer
Exclusion Criteria
- •Contraindication of MRI
- •Failure with informed consent
- •Fail to scan screening protocol
Outcomes
Primary Outcomes
Decrease in LVEF (left ventricular ejection fraction)
Time Frame: 2 years after CMR scanning
Decrease in LVEF : more than 10% compared to the baseline LVEF) or LVEF \< 50%
Secondary Outcomes
- MACE (Major adverse cardiac events)(2 years after CMR scanning)